Alphatec Holdings Cuts Full-Year Revenue Outlook After Q3 Earnings and Estimates Miss Triggers 32% Stock Drop

Alphatec Holdings reported third-quarter 2026 total revenue of $221 million, a 13% year-over-year increase, but the result fell short of Wall Street estimates, sending shares down roughly 32% in premarket trading on October 30. Surgical revenue grew 14% to $202 million, driven by a 17% rise in surgical hardware, with case volumes up 20% and net new surgeon users increasing 25%.

Despite the operational growth, the company cut its full-year 2026 revenue outlook to approximately $862 million from a prior guidance of $882 million, with surgical revenue now expected around $789 million versus the earlier $805 million target, and EOS revenue trimmed to $73 million from $77 million. The revised guidance implies roughly 13% total revenue growth and 15% surgical revenue growth for the year, down from prior targets of 15% and 17%, respectively. Management cited the need for more disciplined execution in biologics to fully translate procedural revenue.

BMO Capital Markets downgraded the stock to Market Perform from Outperform and cut its price target to $8 following the results. The stock was among the sharpest decliners in premarket trading, falling alongside other high-profile names as investors reacted to both the earnings miss and the guidance reduction.